Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2023-07-31 Share Issue/Capital Cha…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Nytt antal aktier och röster i Xspray Pharma
Share Issue/Capital Change Classification · 99% confidence The document announces a change in the number of shares and votes following a rights issue completed in June 2023. This directly relates to changes in the company's capital structure and share count. The filing explicitly mentions the increase in outstanding shares and share capital. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core content is the capital change itself, not just the announcement of a report, making SHA more specific than RPA or RNS.
2023-07-31 Swedish
Xspray Pharma receives request for additional information concerning Dasynoc from FDA
Legal Proceedings Report Classification · 99% confidence The document announces that Xspray Pharma received a Complete Response Letter (CRL) from the FDA requesting additional information regarding their product Dasynoc. This is a specific update concerning a regulatory review process and legal/regulatory interaction, but it is not a full financial report (like 10-K or IR), a dividend announcement, or a management change. It details an ongoing legal/regulatory matter (FDA review feedback). Among the provided codes, 'Legal Proceedings Report (LTR)' is the most appropriate fit for significant updates on regulatory actions or interactions with bodies like the FDA that impact product approval, even if it's not a traditional lawsuit. Since the document is short (4413 chars) and primarily serves as an announcement of an event/update, it could potentially be RNS, but LTR captures the specific nature of the FDA interaction (review feedback/deficiencies) better than the general RNS fallback. Given the context of FDA feedback on an NDA, LTR is selected over the general RNS.
2023-07-11 English
Xspray Pharma erhåller begäran om ytterligare information gällande Dasynoc från FDA
Regulatory Filings Classification · 95% confidence The document is a press release from Xspray Pharma AB detailing an update regarding the FDA's review of their product, Dasynoc. It specifically mentions receiving a Complete Response Letter (CRL) requesting further information regarding dosing instructions and a third-party manufacturing facility. The text is an announcement about regulatory interaction and progress, not the full financial report (10-K, IR) or a formal earnings release (ER). Since it is a specific regulatory update concerning a drug application (NDA) and the company is communicating this development to the market, it fits best under the general category for regulatory announcements that aren't strictly financial or management-related. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, non-financial regulatory update that doesn't match other categories like LTR (Legal Proceedings) or ER/IR (Financial Reports). The document concludes with a statement about being required to publish under EU Market Abuse Regulation, confirming its nature as a regulatory disclosure.
2023-07-11 Swedish
Xspray tillförs cirka 251 MSEK genom en företrädesemission
Capital/Financing Update Classification · 98% confidence The document is a press release from Xspray Pharma AB announcing the outcome of a rights issue ('företrädesemission'). It details the amount raised (approximately 251 MSEK), the subscription rate (83%), and the intended use of funds (launching Dasynoc in the US market). This type of announcement, detailing fundraising activities, capital structure changes, and the resulting capital injection, directly corresponds to the definition of a Capital/Financing Update. Although it mentions a prospectus published on May 30, 2023, the current document is the announcement of the *result* of that financing activity, not the announcement of the report itself (which would be RPA/RNS). Therefore, 'CAP' (Capital/Financing Update) is the most appropriate classification.
2023-06-27 Swedish
Xspray raises approximately SEK 251 million through a rights issue
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the final outcome of a 'rights issue' (a type of fundraising/capital activity). It details the proceeds raised (SEK 251 million), the subscription rates, and the resulting increase in share capital. This directly relates to the company's financing activities and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA), as it contains the substantive results of the financing event itself.
2023-06-27 English
Xspray has published prospectus relating to its previously announced rights issue
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that the prospectus for a previously announced rights issue has been approved by the Swedish Financial Supervisory Authority and made available. The core subject is a capital raising/financing activity (Rights Issue) and the publication of the associated legal document (prospectus). Since the document is an announcement about the availability of a prospectus related to a capital raise, it fits best under 'Capital/Financing Update' (CAP). Although it mentions the publication of a prospectus, the primary focus is the financing event itself, not just the announcement of a report publication (RPA). The document is substantial (12,440 chars) and contains detailed information about the rights issue, advisors, and legal disclaimers, making it more than a simple RPA.
2023-05-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.